AFMD - Affimed starts dosing of blood cancer drug in early-stage trial
2023-03-29 06:51:32 ET
- Affimed ( NASDAQ: AFMD ) said the first patient was dosed in a phase 1 trial of AFM28 monotherapy to treat patients with CD123-positive relapsed/refractory (r/r) acute myeloid leukemia (AML).
- "AFM28 broadens our footprint in hematological malignancies in addition to AFM13’s encouraging clinical activity as a single agent and in combination with NK cells, and adds to our clinically validated pipeline with multiple expected data readouts in 2023," said Affimed CEO Adi Hoess.
- Affimed noted that it also plans to develop AFM28 in combination with allogeneic natural killer (NK) cell therapy.
For further details see:
Affimed starts dosing of blood cancer drug in early-stage trial